Lyell Immunopharma Stock Buy Hold or Sell Recommendation
LYEL Stock | USD 2.67 0.07 2.55% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Lyell Immunopharma is 'Strong Sell'. Macroaxis provides Lyell Immunopharma buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding LYEL positions. The advice algorithm takes into account all of Lyell Immunopharma's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Lyell Immunopharma's buy or sell advice are summarized below:
Real Value 3.63 | Target Price 7 | Hype Value 2.69 | Market Value 2.67 | Naive Value 3.05 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Lyell Immunopharma given historical horizon and risk tolerance towards Lyell Immunopharma. When Macroaxis issues a 'buy' or 'sell' recommendation for Lyell Immunopharma, the advice is generated through an automated system that utilizes algorithms and statistical models.
Lyell |
Execute Lyell Immunopharma Buy or Sell Advice
The Lyell recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Lyell Immunopharma. Macroaxis does not own or have any residual interests in Lyell Immunopharma or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Lyell Immunopharma's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
Strong Sell
Market Performance | Modest | Details | |
Volatility | Very risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Lyell Immunopharma Trading Alerts and Improvement Suggestions
Lyell Immunopharma had very high historical volatility over the last 90 days | |
The company reported the previous year's revenue of 130 K. Net Loss for the year was (234.63 M) with profit before overhead, payroll, taxes, and interest of 84.68 M. | |
Lyell Immunopharma currently holds about 655.56 M in cash with (163.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.64. | |
Lyell Immunopharma has a poor financial position based on the latest SEC disclosures | |
Roughly 73.0% of the company shares are owned by institutional investors | |
Latest headline from investorplace.com: LYEL Stock Earnings Lyell Immunopharma Beats EPS for Q1 2024 |
Lyell Immunopharma Returns Distribution Density
The distribution of Lyell Immunopharma's historical returns is an attempt to chart the uncertainty of Lyell Immunopharma's future price movements. The chart of the probability distribution of Lyell Immunopharma daily returns describes the distribution of returns around its average expected value. We use Lyell Immunopharma price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Lyell Immunopharma returns is essential to provide solid investment advice for Lyell Immunopharma.
Mean Return | 0.86 | Value At Risk | -7.17 | Potential Upside | 9.62 | Standard Deviation | 6.37 |
Return Density |
Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Lyell Immunopharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Lyell Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Lyell Immunopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Lyell Immunopharma backward and forwards among themselves. Lyell Immunopharma's institutional investor refers to the entity that pools money to purchase Lyell Immunopharma's securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Millennium Management Llc | 2024-03-31 | 2 M | Mic Capital Management Uk Llp | 2023-12-31 | 1.7 M | Bank Of America Corp | 2023-12-31 | 1.7 M | Massachusetts Financial Services Company | 2024-03-31 | 1.5 M | Northern Trust Corp | 2023-12-31 | 1.5 M | Charles Schwab Investment Management Inc | 2024-03-31 | 1.3 M | Goldman Sachs Group Inc | 2023-12-31 | 1.3 M | Td Asset Management Inc | 2024-03-31 | 963.8 K | Invenomic Capital Management, Lp | 2023-12-31 | 746.4 K | Mwg Management Ltd. | 2023-12-31 | 20.2 M | Orland Properties Ltd | 2023-12-31 | 15.1 M |
Lyell Immunopharma Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Lyell Immunopharma or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Lyell Immunopharma's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Lyell stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | 0.88 | |
β | Beta against NYSE Composite | -0.45 | |
σ | Overall volatility | 6.14 | |
Ir | Information ratio | 0.12 |
Lyell Immunopharma Volatility Alert
Lyell Immunopharma is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Lyell Immunopharma's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Lyell Immunopharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Lyell Immunopharma Fundamentals Vs Peers
Comparing Lyell Immunopharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Lyell Immunopharma's direct or indirect competition across all of the common fundamentals between Lyell Immunopharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as Lyell Immunopharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Lyell Immunopharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing Lyell Immunopharma by comparing valuation metrics with those of similar companies.
Better Than Average | Worse Than Average | Compare Lyell Immunopharma to competition |
Fundamentals | Lyell Immunopharma | Peer Average |
Return On Equity | -0.33 | -0.31 |
Return On Asset | -0.19 | -0.14 |
Current Valuation | 234.06 M | 16.62 B |
Shares Outstanding | 254.94 M | 571.82 M |
Shares Owned By Insiders | 15.00 % | 10.09 % |
Shares Owned By Institutions | 73.24 % | 39.21 % |
Number Of Shares Shorted | 19.97 M | 4.71 M |
Price To Earning | 3.66 X | 28.72 X |
Price To Book | 1.17 X | 9.51 X |
Price To Sales | 5,883 X | 11.42 X |
Revenue | 130 K | 9.43 B |
Gross Profit | 84.68 M | 27.38 B |
EBITDA | (213.84 M) | 3.9 B |
Net Income | (234.63 M) | 570.98 M |
Cash And Equivalents | 655.56 M | 2.7 B |
Cash Per Share | 2.64 X | 5.01 X |
Total Debt | 63.17 M | 5.32 B |
Debt To Equity | 0.08 % | 48.70 % |
Current Ratio | 13.26 X | 2.16 X |
Book Value Per Share | 2.37 X | 1.93 K |
Cash Flow From Operations | (163.69 M) | 971.22 M |
Short Ratio | 21.75 X | 4.00 X |
Earnings Per Share | (0.90) X | 3.12 X |
Price To Earnings To Growth | 0.68 X | 4.89 X |
Target Price | 6.33 | |
Number Of Employees | 224 | 18.84 K |
Beta | -0.55 | -0.15 |
Market Capitalization | 698.53 M | 19.03 B |
Total Asset | 750.03 M | 29.47 B |
Retained Earnings | (1 B) | 9.33 B |
Working Capital | 520.17 M | 1.48 B |
Net Asset | 750.03 M |
Note: Disposition of 145380 shares by Bishop Hans Edgar of Lyell Immunopharma at 0.1 subject to Rule 16b-3 [view details]
Lyell Immunopharma Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Lyell . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
Daily Balance Of Power | (9,223,372,036,855) | |||
Rate Of Daily Change | 0.97 | |||
Day Median Price | 2.67 | |||
Day Typical Price | 2.67 | |||
Price Action Indicator | (0.04) | |||
Period Momentum Indicator | (0.07) |
About Lyell Immunopharma Buy or Sell Advice
When is the right time to buy or sell Lyell Immunopharma? Buying financial instruments such as Lyell Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 67.8M | 67.7M | 63.2M | 61.8M | Total Assets | 1.1B | 937.6M | 750.0M | 941.4M |
Use Investing Ideas to Build Portfolios
In addition to having Lyell Immunopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Marijuana Thematic Idea Now
Marijuana
Small and mid-cap equities that are involved in production and delivery of Marijuana products. This theme is designed for investors that are willing to accept higher levels of market risk inherited by Marijuana production in the United States. The Marijuana theme has 49 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Marijuana Theme or any other thematic opportunities.
View All Next | Launch |
Check out Lyell Immunopharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.Note that the Lyell Immunopharma information on this page should be used as a complementary analysis to other Lyell Immunopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Complementary Tools for Lyell Stock analysis
When running Lyell Immunopharma's price analysis, check to measure Lyell Immunopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lyell Immunopharma is operating at the current time. Most of Lyell Immunopharma's value examination focuses on studying past and present price action to predict the probability of Lyell Immunopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lyell Immunopharma's price. Additionally, you may evaluate how the addition of Lyell Immunopharma to your portfolios can decrease your overall portfolio volatility.
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |
Is Lyell Immunopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyell Immunopharma. If investors know Lyell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyell Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.90) | Quarterly Revenue Growth (0.95) | Return On Assets (0.19) | Return On Equity (0.33) |
The market value of Lyell Immunopharma is measured differently than its book value, which is the value of Lyell that is recorded on the company's balance sheet. Investors also form their own opinion of Lyell Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Lyell Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyell Immunopharma's market value can be influenced by many factors that don't directly affect Lyell Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyell Immunopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyell Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyell Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.